Our Translational Science Platform utilizes a suite of integrated technologies to profile the immune cellular and molecular characteristics within thousands of human solid tumors, providing critical information on the tumor micro-environment (TME) that allows us to identify and guide new immunotherapies more efficiently through development. We utilize a systematic approach to match targets to defined patient populations that we believe are more likely to benefit from these therapies – allowing us to distinguish and prioritize targets versus making a more random choice. If our biomarker-driven strategies are successful, we anticipate developing a companion diagnostic for each product. We believe that we can facilitate a systematic means of novel immunotherapy discovery, enroll biomarker-defined patient populations in clinical trials, and develop therapies, alone or in combination, that will have a meaningful and long-lasting impact on the lives of cancer patients.
What does that mean for patients? If our strategies are successful, we anticipate more robust and rapid achievement of human proof of concept and shorter times to deliver novel therapies to patients with unmet needs.